All In Biotech

Drug Trial Radar · NCT07913347

Safety, Dosage, and Microbiome Engraftment Study of MGT-006 for Ulcerative Colitis (ROOT Study)

Phase 1b/2a Study of MGT-006 in Patients With Ulcerative Colitis: A Dose and Preparation Regimen Selection Trial to Assess Safety and Microbiome Engraftment (ROOT Study)

Last checked: Nov 19, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

54

Planned (sponsor's estimate)

Start

Jul 9, 2026

Primary completion

Mar 31, 2028

Study completion Sep 30, 2028

Sponsor

Lead sponsor
Metagen Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Nov 3, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Ulcerative colitis is a condition that causes inflammation and ulcers in the large intestine. MGT-006 is an investigational oral capsule containing viable gut microbiota from screened human donors. This study will evaluate the safety and tolerability of MGT-006 in adults with moderately active ulcerative colitis. It will also examine whether gut microbiota from MGT-006 engraft in participants' intestines and explore changes in ulcerative colitis symptoms and inflammation. The study has two parts. In Phase 1b, participants will be randomly assigned to receive MGT-006 either without antibiotic pretreatment or after five days of oral vancomycin or AFM (Amoxicillin/Fosfomycin/Metronidazole) pretreatment. MGT-006 will be taken for eight weeks, followed by four weeks of observation. Phase 2a is planned to explore different doses and potentially different dosing regimens of MGT-006, using the pretreatment approach selected from Phase 1b. The final Phase 2a design will depend on the Phase 1b findings and will be specified in an amended protocol before Phase 2a begins.

Conditions

  • Ulcerative Colitis (UC)
  • Ulcerative Colitis, Active Moderate

Interventions

  • MGT-006Drug

    MGT-006 is an investigational enteric-coated oral capsule filled with lyophilized human fecal material containing viable gut microbiota. In Phase 1b, four capsules are taken three times daily before meals for 56 days (12 capsules per day). Dose reduction, interruption, discontinuation, and re-escalation may occur according to protocol-defined safety rules. Phase 2a doses, dosing frequency, and treatment duration will be determined based on Phase 1b findings and specified in an amended protocol.

  • Vancomycin hydrochlorideDrug

    Vancomycin hydrochloride is administered orally as pretreatment at a total daily dose of 500 mg (as vancomycin), divided into four daily administrations, for five days before MGT-006. In Phase 1b, it is administered only to participants randomized to the vancomycin pretreatment arm. Its use in Phase 2a depends on the pretreatment approach selected from Phase 1b.

  • Amoxicillin hydrate/ Fosfomycin calcium hydrate/ MetronidazoleDrug

    Subjects allocated to the AFM group will receive pretreatment antibiotics for 5 days after final registration. Amoxicillin hydrate 1500 mg/day (as amoxicillin), fosfomycin calcium hydrate 3000 mg/day (as fosfomycin), and metronidazole 750 mg/day will be orally administered three times a day for 5 days. Its use in Phase 2a depends on the pretreatment approach selected from Phase 1b.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety and tolerability of MGT-006 (adverse events, adverse reactions)Time frame: Phase 1b: From first administration of study medication(MGT-006 or antibiotics) through four weeks after completion of MGT-006 treatment.

Locations

12 sites in 2 countries. Site status is shown where the registry gives one.

  • GI PROS, Inc.

    Naples, Florida · Not yet recruiting

  • Brigham and Women's Hospital

    Boston, Massachusetts · Not yet recruiting

  • NYU Langone Health

    New York, New York · Not yet recruiting

  • Fukuoka University Hospital

    Fukuoka, Fukuoka, Japan · Recruiting

  • Sapporo Medical University Hospital

    Sapporo, Hokkaido, Japan · Recruiting

  • Kawasaki Medical School Hospital

    Kurashiki, Okayama-ken, Japan · Recruiting

  • Kansai Medical University Hospital

    Hirakata, Osaka, Japan · Recruiting

  • Hamamatsu University Hospital

    Hamamatsu, Shizuoka, Japan · Recruiting

  • Juntendo University Hospital

    Bunkyō-Ku, Tokyo, Japan · Recruiting

  • The Jikei University Hospital

    Minato-Ku, Tokyo, Japan · Recruiting

  • Kitasato University Kitasato Institute Hospital

    Minato-Ku, Tokyo, Japan · Recruiting

  • Kyorin University Hospital

    Mitaka, Tokyo, Japan · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.